Sellas Life Sciences is trading 5.8% down now at $12.43 after shareholders approved the issuance of 20 million new shares for employee compensation, raising significant dilution concerns.
- The approved equity plan includes a specific 1.07 million-share award to the company's CEO.
- The decline follows a highly volatile 12.26% surge on Friday, as investors engage in profit-taking and speculative trading.
- The move comes amid continued market focus on the biotech firm's clinical pipeline and expanded share pool.